35
Participants
Start Date
August 30, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
[225Ac]Ac-FL-020
\[225Ac\]Ac-FL-020 injected intravenously
Blood samples for PK
Following the first injection of \[225Ac\]Ac-FL-020, blood samples after treatment will be collected for PK evaluation.
[111In]In-FL-020
A dose of \[111In\]In-FL-020 will be injected prior to the first dose of \[225Ac\]Ac-FL-020 for dosimetry evaluation
Blood and urine samples collection
For dosimetry evaluation and urine excretion assessment, blood and urine samples will be collected after the injection of \[111In\]In-FL-020
SPECT/CT images
For dosimetry evaluation, SPECT/CTs will be performed following the injection of \[111In\]In-FL-020.
RECRUITING
City of Hope Medical Center, Duarte
RECRUITING
Chao Family Comprehensive Cancer Center, Irvine
RECRUITING
University of Stanford, Stanford
RECRUITING
Princess Alexandra Hospital, Brisbane
RECRUITING
Genesiscare Murdoch, Murdoch
RECRUITING
MacQuarie University Clinical Trial Unit, Sydney
Lead Sponsor
Full-Life Technologies GmbH
INDUSTRY